Stephens Consulting’s Moderna MRNA Stock Holding History

Stephens Consulting’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$177	Sell	6 -494	-99%	-$13.4K	﹤0.01%	459
2025 Q3	$12.9K	Hold	500	–	–	﹤0.01%	215
2025 Q2	$13.8K	Sell	500 -46	-8%	-$1.21K	﹤0.01%	301
2025 Q1	$15.5K	Hold	546	–	–	﹤0.01%	284
2024 Q4	$22.7K	Hold	546	–	–	0.01%	260
2024 Q3	$36.5K	Hold	546	–	–	0.01%	212
2024 Q2	$64.8K	Hold	546	–	–	0.02%	161
2024 Q1	$58.2K	Buy	546 +46	+9%	+$4.64K	0.02%	168
2023 Q4	$49.7K	Hold	500	–	–	0.02%	180
2023 Q3	$51.6K	Hold	500	–	–	0.02%	163
2023 Q2	$60.8K	Sell	500 -500	-50%	-$66.7K	0.02%	145
2023 Q1	$154K	Sell	1,000 -2	-0.2%	-$330	0.09%	86
2022 Q4	$180K	Hold	1,002	–	–	0.12%	78
2022 Q3	$118K	Hold	1,002	–	–	0.11%	93
2022 Q2	$143K	Sell	1,002 -53	-5%	-$7.58K	0.12%	82
2022 Q1	$182K	Sell	1,055 -507	-32%	-$85.4K	0.15%	85
2021 Q4	$397K	Buy	+1,562	New	+$457K	0.33%	49

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Stephens Consulting's MRNA Position: Q4 2025 in Review

Stephens Consulting reduced its Moderna (MRNA) stake by 99% in Q4 2025, selling an estimated $13.4K and leaving 6 shares worth $177. The position accounts for ﹤0.01% of the portfolio, ranked #459.

Stephens Consulting first reported a position in MRNA in Q4 2021 and has held it in 17 quarters since. The position peaked at $397K in Q4 2021. 673 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

Stephens Consulting held 6 shares of Moderna worth $177 as of Q4 2025.
Stephens Consulting sold 494 Moderna shares in Q4 2025, an estimated $13.4K.
Moderna made up ﹤0.01% of Stephens Consulting's portfolio in Q4 2025, its #459 holding.
Stephens Consulting first reported a position in Moderna in Q4 2021 and has held it in 17 quarters since.
Stephens Consulting's Moderna position peaked at $397K in Q4 2021.
673 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.